Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Yiming Pharmaceutical) was established in December 2003. It is a comprehensive pharmaceutical enterprise integrating R&D, production and sales. The company is headquartered in the National Economic and Technological Development Zone of Lhasa City, Tibet Autonomous Region, and owns Beijing Yiming Kangyuan Pharmaceutical Technology Co., Ltd., Chengdu Yiming Kangyuan Pharmaceutical Technology Co., Ltd., Lhasa Yiming Kangyuan Pharmaceutical Technology Co., Ltd., and Beijing Yiming Haizhong Investment Management Co., Ltd. and Sichuan Viao Pharmaceutical Co., Ltd. The planting base is located in Linzhi, Tibet, the production base is located in Lhasa and Pengzhou, Sichuan, and the marketing network is spread all over the country.

The company has always been committed to the treatment of chronic diseases such as diabetes and cardiovascular diseases and the development and research of core products in the field of gynecological obstetrics. The company's core products Yiming® Aotianpin® Miglitol Tablets and Xintong® Trichosanthes skin injection Liquid, Yimefen® Namefen Hydrochloride Injection, Yiming® Xinnuoshu® Carbecoxon Injection, Yiming® Meixiaodan® Red Gold Xiaojie Tablets, Weipufen® Aceclofenac Intestine All dissolved tablets have been included in the national medical insurance catalog. General medicine products are widely involved in antibiotics, anti-allergics, and digestive systems.

The company has always adhered to the corporate philosophy of "simple, pragmatic, innovative and win-win", is simple and practical; adheres to the business philosophy of R&D-driven and result-oriented, and now has invention patents including many domestic first drug patents and award-winning patents. , new drug certificate and drug production registration approval document.

The enterprises have successively obtained "Tibet Autonomous Region Science and Technology Small and Medium Enterprises", "National High-tech Enterprises", "National Science and Technology Incubation Enterprises", "Tibet National Science and Technology Incubation Enterprises", and "China Cardiovascular and Cerebrovascular Disease Diagnosis and Treatment Industry Technology Innovation Strategic Alliance ( Tibet)”, “China Patent Excellence Award” and other honors. In recent years, Yiming Pharmaceutical has developed rapidly due to Tibet's unique biological resources advantages and national policy advantages. It was officially listed on the Shenzhen Stock Exchange on December 9, 2016.

In the future, the company will continue to utilize its core product advantages, analyze and grasp the challenges and opportunities faced by the market from multiple aspects, adapt to the country's new medical system reform and development model, and systematically build a high-quality human resources management system, financial management system, and operation and development system. . Taking entry into the capital market as a new opportunity, taking "helping patients overcome diseases and always safeguarding people's health" as the corporate vision, and taking high-quality, high-priced and significant clinical value drugs as the soul, shouldering the social responsibilities that Chinese pharmaceutical companies should have , pursue excellence and strive to become a forefront of China's chronic disease field.